Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn’t top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company’s prospects. Slimming products for fat profits The great opportunities … Read more
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07, while the Dow edged down 0.03% to 41,989.96. Market optimism was supported by a 0.7% rise in U.S. construction spending for February. Even so, uncertainty persists as President Donald Trump’s “Liberation Day” … Read more
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector. That’s exactly what happened when J.P. Morgan recently upgraded Gilead Sciences Inc. NASDAQ: GILD, highlighting renewed confidence … Read more
Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements. The day’s gain was powered by the telehealth company’s announcement of plans to sell the … Read more
Novo Nordisk‘s (NVO 1.47%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company’s news, a performance that easily beat the recovering S&P 500‘s (^GSPC -1.39%) 1.1% gain. The story was different with Hims & Hers Health (HIMS -7.04%), which … Read more
Novo Nordisk‘s (NVO 1.47%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company’s news, a performance that easily beat the recovering S&P 500‘s (^GSPC -1.39%) 1.1% gain. The story was different with Hims & Hers Health (HIMS -7.04%), which … Read more
Roller-coaster healthcare stock Hims & Hers Health (HIMS 8.47%), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday. Shares of the pharmaceutical upstart are flying Tuesday morning — up 7.3% through 10:20 a.m. ET. … Read more
Shares of Hims & Hers Health Inc. NYSE: HIMS have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share. Now, this is where most investors would throw … Read more
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (HIMS 9.07%) plummeted following its fourth-quarter earnings report. The stock had rocketed from around $24 at the start of the year to over $70 before pulling back. Investors became excited about the prospects of the company, while its Super … Read more
Hims & Hers (HIMS 5.09%) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty healthcare company on that slump, which helped Hims & Hers recover by more than 5% in mid-week action. That was more than good enough … Read more